The Global Recombinant Human Serum Albumin (HSA) Market is on an upward trajectory, poised to reach a projected value of USD 116.42 million by the year 2027, up from USD 62.11 million in 2019. This impressive growth is underpinned by a compound annual growth rate (CAGR) of 8.2% throughout the forecast period. This burgeoning market is being driven by the widespread application of recombinant DNA technology across various sectors, including drug delivery, drug formulation, cell culture media, vaccine production, and plasma research in laboratory settings.

Albumins, a group of acidic proteins found in human bodily fluids, as well as in plant and mammal tissues, play a pivotal role in regulating colloidal osmotic pressure in the blood. In the human body, albumin is primarily produced in the liver, subsequently diffusing into the bloodstream to regulate blood volume while also facilitating the transportation of molecules such as bile salts, ions, hormones, and other essential substances. Albumin can be categorized into three main types: bovine serum albumin, recombinant albumin, and human serum albumin.

Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/3524

Recombinant human serum albumin is currently experiencing high demand due to its vital role in replenishing lost fluids and restoring blood volume in critical medical conditions such as severe burn injuries, fetal erythroblastosis, hypoproteinemia, and various surgeries. Its hydrophobic properties allow it to efficiently transport a variety of ligands, making it a sought-after choice for drug delivery applications. Furthermore, it is utilized in therapeutic medicine to treat low albumin levels resulting from conditions like dialysis, surgery, abdominal infections, pancreatitis, liver failure, respiratory distress, ovarian disorders linked to fertility drugs, bypass surgery, and other health-related issues. The extensive medical applications of recombinant human serum albumin are expected to bolster its market share significantly.

The global vaccination drive, where millions receive cell culture-based vaccines annually, and the increasing use of cell culture-based therapeutics for various disorders are anticipated to further boost revenue in this sector. Moreover, ongoing improvements in molecular separation technology and protein purification systems will support the expansion of the industry.

In 2017, the Food and Drug Administration in China granted approval for clinical trials involving human blood albumin derived from transgenic rice seeds. The rising number of FDA approvals for research and the development of contract research manufacturing of drugs are also expected to drive trends in the recombinant human serum albumin market up to 2027.

However, challenges persist, as albumin sourced from human plasma can potentially contain viruses, bacteria, and other infectious agents, despite treatment to eliminate them. This poses a risk to industry growth.

In terms of product type, OsrHSA is expected to witness substantial growth due to its higher purity and consistent batch quality compared to alternatives like FBS, BSA, and pHSA. OsrHSA is derived from rice grains through recombinant technology and serves as an excellent excipient, stabilizer, and embedding agent in biopharmaceutical applications.

To know more about the latest insights of the report, visit @

https://www.reportsanddata.com/request-latest-insight/3524

Regarding applications, the cell culture media segment is projected to achieve the highest CAGR through 2027. Plasma-derived human serum albumin plays a crucial role in manufacturing cell culture-based vaccines and therapeutics, enhancing cell growth and protein productivity.

In 2019, North America emerged as the leading contributor to global recombinant human serum albumin market revenue, and this trend is expected to continue through 2027. The region benefits from increased approval of albumin products and a favorable medical research environment. However, the Asia-Pacific region is predicted to register the highest CAGR during the analysis period, driven by rising healthcare expenditure and growing awareness of DNA recombinant technology-based treatments.

Key players in the recombinant human serum albumin market include Albumedix, Merck, Ventria (InVitria), NCPC, Oryzogen, HiMedia, Boehringer Ingelheim, Regeneron Pharmaceuticals, Eli Liily, Bristol-Myers Squibb, Novartis, Celldex Therapeutics, Takeda, GlaxoSmithKline, Roche, and Cyagen Biosciences. These industry leaders are adopting diverse strategies such as acquisitions, mergers, collaborations, new product development, and capacity expansion to fuel market growth. Notably, Merck secured FDA approval for ERVEBO® in December 2019, a vaccine derived from recombinant human serum albumin that effectively prevents disease caused by Zaire ebolavirus in individuals aged 18 years and older.

In conclusion, the global recombinant human serum albumin market is on a robust growth trajectory, driven by diverse applications and technological advancements. While North America leads in revenue contribution, the Asia-Pacific region is poised for significant growth, offering promising opportunities for industry players. The industry's future growth will likely be shaped by ongoing research and development efforts, strategic partnerships, and expanding product portfolios.

Request a customized copy of the report @ https://www.reportsanddata.com/request-customization-form/3524

Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.  

Browse for more reports:

Hematologic Malignancies Testing Market

Advanced Ophthalmology Technologies Market

Electrocardiogram (ECG) Management Systems Market

Nonmydriatic Handheld Fund Camera Market

Empty Intravenous (IV) Bags Market

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com

Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports

Browse More Latest Reports @ https://www.reportsanddata.com/report